Daniel Skovronsky
Daniel Skovronsky's purchase track record
Daniel Skovronsky has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2025 | LLY | $634K | +54.9% | +60.9% | +7.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| ILMN | ▲ Buy | Grant | 1,674 | $275K | 6/16/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| LLY | ▲ Buy | Grant | 15,548 | $16.2M | 2/9/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 5,641 | $5.9M | 2/1/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 12,684 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Gift | 179 | $0 | 11/10/2025 | View on chart |
| LLY | ▲ Buy | Open Market | 1,000 | $634K | 8/12/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 49,796 | $0 | 6/5/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 340 | $294K | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Grant | 18,772 | $16.3M | 2/10/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 3,950 | $3.4M | 2/10/2025 | View on chart |
| LLY | ▼ Sell | Open Market | 710 | $615K | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 8,989 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 4,004 | $3.2M | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Gift | 5,724 | $0 | 9/11/2024 | View on chart |
| LLY | ▼ Sell | Gift | 111 | $0 | 9/10/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,695 | $0 | 6/6/2024 | View on chart |
| LLY | ▲ Buy | Grant | 12,910 | $9.5M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 9,941 | $0 | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 4,434 | $2.9M | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Gift | 17 | $0 | 11/10/2023 | View on chart |
| LLY | ▼ Sell | Gift | 249 | $0 | 8/10/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 15,151 | $0 | 6/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 18,388 | $6.3M | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 15,675 | $0 | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 7,035 | $2.4M | 2/1/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 17,275 | $0 | 6/2/2022 | View on chart |
| LLY | ▲ Buy | Grant | 22,581 | $5.5M | 2/9/2022 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 8,437 | $2.1M | 2/1/2022 | View on chart |
| LLY | ▲ Buy | Option Exercise | 18,735 | $0 | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.